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Summary
Purpose: To evaluate the efficacy and tolerability of levetiracetam (LEV) as either ‘de
novo’ (monotherapy) or ‘add-on’ therapy in patients with different generalised
epilepsies characterised by myoclonic seizures from an observational study.
Methods: We evaluated 35 patients (21 female, mean age 24.7 years) with different
types of generalised epilepsies (juvenile myoclonic epilepsy (JME), severe myoclonic
epilepsy of infancy (SMEI), Lennox—Gastaut syndrome (LGS), myoclonic-astatic epi-
lepsy (MAE), myoclonic absences (MA), benign myoclonic epilepsy in infancy (BMEI)
and 4 patients had unspecified epileptic syndromes). Patients received LEVas de novo
monotherapy or add-on therapy. Seizure frequency changes and adverse events were
observed. Follow-up was conducted for a period of 12 months after treatment.
Results: Patients received LEV 2000—3000 mg/day as de novo (n = 8) and as add-on
therapy. In total, 29 (82%) of the 35 patients achieved 50% seizure frequency
reduction, 15 (42%) patients achieved seizure freedom while a further 14 (40%)
patients achieved 50—99% seizure frequency reduction. Six (17%) patients discon-
tinued LEV due to inefficacy or seizure worsening. Not even a single patient discon-
tinued due to adverse effects.
Conclusions: Our results confirm that LEV as de novo (monotherapy) and add-on
therapy at doses between 2000 and 3000 mg/day effectively reduces myoclonic
seizure frequency in patients with generalised epilepsy. LEV was also well-tolerated.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +39 0961 712415; fax: +39 0961 777775.
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Table 1 Patient characteristics
Total patients n = 35
Characteristics
Sex N (%)
Female 21 (60.0)
Male 14 (40.0)
Age Years
Mean (S.D.) 24.7 (10.6)
Median 26
Range 3—44
Type of epilepsy N (%)
Juvenile myoclonic epilepsy (JME) 21 (60.0)
Severe myoclonic epilepsy
of infancy (SMEI)
4 (11.4)
Lennox—Gastaut syndrome (LGS) 2 (5.7)
Benign myoclonic epilepsy in
infancy (BMEI)
1 (2.9)
Myoclonic-astatic epilepsy (MAE) 1 (2.9)
Myoclonic absences (MA) 1 (2.9)
Unspecified 5 (14.3)
Age of seizure onset Years
Mean (S.D.) 8.9 (6.1)
Median 10
Range 0.25—21Introduction
Levetiracetam (LEV) is a novel antiepileptic drug
recently approved in the United States for the
treatment of partial epilepsies with or without
secondary generalisation.1 One year later, LEV
was also approved in Europe with the same indica-
tion. LEV is very similar to piracetam which is
commonly used in high doses to treat cortical
myoclonus.2 They are both pyrrolidone derivatives
that share similar chemical structures but have
distinct pharmacological profiles and uses.2,3
Although LEV is chemically similar to piracetam,
its mechanism of action is not yet clarified. How-
ever, animal models have shown that LEV antago-
nizes neuronal hypersynchronization during a
seizure.4 Furthermore, several studies have
demonstrated that LEV also works in patients
with generalised epilepsy and cortical myoclonus
too.4,5
In this study, we aimed to evaluate the efficacy
and tolerability of LEV as either ‘de novo’ (mono-
therapy) or ‘add-on’ therapy in patients with dif-
ferent types of generalised epilepsy characterised
by myoclonic seizures.
Patients and methods
From September 2004, we recruited patients diag-
nosed of generalised epilepsy who visited the epi-
lepsy clinic, University of Catanzaro for an open
study. The study group consisted of 35 patients
(mean age 24.7  10.5; 21 females). The study
was approved by the University Hospital Ethics
Committee, and all subjects and their guardians
in case of children, granted informed consent to
participate.
In all patients the diagnosis of generalised epi-
lepsy was based on the International Classification
of Epilepsies.6 All clinical records were analyzed.
The following clinical characteristics were noted:
sex, age, AEDs used prior to LEV, age of epilepsy
onset, frequency of seizures, abnormal neurological
examination, family history of epilepsy, laboratory
findings. Seizure types were identified according to
the classification of epileptic seizures and syn-
dromes by the International League Against Epi-
lepsy.6 All patients underwent several interictal
electroencephalograms (EEG) including routine
awake and sleep EEGs. Some of the patients had a
clinical MRI (1.5 T) examination done, based on a
protocol routinely used for patients with epilepsy,
including T2-weighted images, and a coronal 3D
sequence with contiguous slices, with and without
administration of gadolinium.LEV was started at the dose of 500 mg/day and
was progressively increased to a mean dose of
2000—3000 mg/day. Only three patients (the
youngest ones) received a lower dose of LEV
between 1000 and 1500 mg daily. The mean dose
was reached within 4 weeks. Patients were clini-
cally observed every 3 months. First of all we
observed the side effects and tolerability of LEV.
Secondly, the efficacy was assessed by measuring
changes in seizure frequency, especially myoclonic
jerks. The basis for comparison was defined as the
myoclonic seizure frequency in the 6 months prior
to the commencement of treatment. We classified
patients post-treatment into three categories:
those achieving seizure freedom, those achieving
between 50 and 99% reduction in seizures, and
those with worsening. Two trained epileptologists
were asked to grade the seizures.
We observed the reduction of massive or focal
epileptic myoclonus and other generalised seizures
(e.g. absence, tonic—clonic).Results
Clinical characteristics of patients are summarized
in Table 1. In details, 21 out of 35 (18 females) had
juvenile myoclonic epilepsy (JME); four (males) had
severe myoclonic epilepsy of infancy (SMEI); two
(females) had Lennox—Gastaut syndrome (LGS); one
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Figure 1 The percentage of patients who responded to
LEV therapy.(male) had myoclonic-astatic epilepsy (MAE); one
(male) had myoclonic absences (MA), and one
(male) had benign myoclonic epilepsy in infancy
(BMEI). The remaining five patients (2 males) had
unspecified epileptic syndromes. In details, all
patients had myoclonic seizures; 11 patients had
also generalised tonic—clonic seizures, two patients
had also absences and seven had both.
Out of 35, eight (22.9%) patients received LEV as
de novo monotherapy while 27 (77.1%) as add-on
therapy to other drugs (e.g. lamotrigine, valpro-
ate). All eight patients who received LEV monother-
apy had JME.
Patients received LEV treatment for a mean of
34.06 (12.74) months and followed up at 28.4
months on average (range 5—52). As shown in
Fig. 1, 29 (83%) patients demonstrated a 50%Table 2 Details of baseline therapy and response to LEV treatment in patients receiving add-on therapy (n = 27), by
epilepsy type
Type of
epilepsy
AED therapy
at baseline
No. of seizures/
month
Reason for
add-on therapy
Age add-on
(year)
Response to
LEV therapy
JME LTG 5 Dysmenorrhoea 24 Seizure freedom
JME VPA 4 Encephalopathy 32 Seizure freedom
JME LTG 7 Poor efficacy 32 Seizure freedom
JME LTG 7 Poor efficacy 17 Seizure freedom
JME LTG 6 Poor efficacy 25 Seizure freedom
JME LTG 7 Poor efficacy 38 Seizure freedom
JME VPA + ACZ 5 Tremor (VPA) 2 Seizure freedom
JME VPA + LTG 8 Poor efficacy (LTG),
dysmenorrhea (VPA)
36 Seizure freedom
JME LTG 7 Poor efficacy 19 50—99% seizure reduction
JME PB + PHT + TPM 6 Poor efficacy (LTG),
tremor (VPA)
15 50—99% seizure reduction
JME LTG + CZP + PB 5 Poor efficacy
(LTG + CZP)
29 50—99% seizure reduction
JME VPA 5 Poor efficacy 28 No change
JME PB + CZP + ACZ 6 Poor efficacy
(CZP, ACZ, PB)
19 Increase in seizures
SMEI VPA + CZP 6 Poor efficacy 7 50—99% seizure reduction
SMEI VPA + CZP 7 Poor efficacy (VPA) 8 50—99% seizure reduction
SMEI LTG + PB + CBZ 4 Poor efficacy (LTG) 7 50—99% seizure reduction
SMEI VPA + PB + ACZ + CZP 8 Poor efficacy
(VPA + CZP + ACZ)
9 No change
LGS PB + TPM + CBZ 5 Action tremor 9 50—99% seizure reduction
LGS VPA + CZP + CBZ 7 Poor efficacy
(VPA + CZP)
11 Increase in seizures
BMEI VPA 5 Hyperammonemia 6 Seizure freedom
MAE VPA + LTG 6 Poor efficacy (VPA) 9 50—99% seizure reduction
MA VPA + TPM 5 Poor efficacy (VPA) 13 50—99% seizure reduction
Unspecified LTG + VPA 5 Poor efficacy 33 Seizure freedom
Unspecified PB + TPM 4 Poor efficacy 31 50—99% seizure reduction
Unspecified LTG + CZP + VPA 4 Poor efficacy (LTG) 27 50—99% seizure reduction
Unspecified VPA + PB + PHT 6 Hair loss (VPA) 23 50—99% seizure reduction
Unspecified VPA 5 Poor efficacy 22 50—99% seizure reduction
ACZ, acetazolamide; CBZ, carbamazepine; CZP, clonazepam; LTG, lamotrigine; PB, phenobarbital; PHT, phenytoin; TPM, topiramate;
VPA, valproic acid.
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Figure 2 The efficacy (% of seizure reduction) of LEV
treatment by epilepsy type.seizure frequency reduction, comprising six of eight
(75%) patients who received LEV monotherapy and
23 on 27 (85%) patients who received LEV add-on
therapy. Of these 35 subjects, 15 (43%) patients
achieved seizure freedom and a further 14 (40%)
patients showed a seizure frequency reduction of
50—99%.
Seizure frequency following LEV therapy
remained unchanged in four (11.4%) out of 35
patients and worsened in two (5.7%) patients.
Of the eight patients who received LEV mono-
therapy (all JME), five (62.5%) patients achieved
seizure freedom and one (12.5%) demonstrated a
50—99% seizure frequency reduction; seizure fre-
quency remained unchanged in one (12.5%) patient
and worsened in one (12.5%) patient.
The response of patients who received LEV add-
on therapy (n = 27), and the reasons for add-on
therapy, are shown in Table 2. Ten of 27 (37%)
patients who received add-on therapy achieved
seizure freedom and 13/27 (48.1%) patients demon-
strated a 50—99% seizure frequency reduction
whereas seizure frequency remained unchanged in
two (7.4%) patients and worsened in two (7.4%)
patients (Table 2).
The efficacy of LEV treatment by epilepsy type is
shown in Fig. 2. No changes on interictal EEGs were
observed.
Six out of 35 (17.1%) patients discontinued LEV
treatment. Reasons for discontinuation were lack
of efficacy (n = 4) and worsening in seizure fre-
quency (n = 2). No patients discontinued treatment
due to AEs.Discussion
LEV is chemically related to piracetam which has
been previously used to treat cortical myoclonus but
its mechanism of action is not yet clarified. Recentstudies reported the efficacy of LEV in the treatment
of myoclonus and progressive myoclonic epilep-
sies.2—10 These studies showed that LEV is very
well-tolerated in adults and children even at high
doses.2—10 Our study further supports this knowl-
edge and reinforces the concept that LEV works very
well in the treatment of epileptic myoclonus.
We observed for several months 35 consecutive
patients referring to our Institute with different
types of epilepsy but all characterised by prominent
myoclonic seizures. We used LEV at common dosage
between 2000 and 3000 mg/day with the exception
of three young patients. Myoclonus dramatically
responded to the LEV and indeed a total of 29
patients obtained seizure reduction. Of these, 15
patients achieved seizure freedom and 14 patients
experienced50—99% seizure frequency reduction.
The seizure frequency reduction and in particular
the antimyoclonic efficacy was greatest among
patients with JME that assumed either de novo or
add-on LEV therapy. On the other hand, the
unchanged or worsened seizure frequency was
greater in patients with refractory generalised epi-
lepsy (SMEI and LGS). Our results may represent an
interesting point because LEV might be a very good
alternative to other antiepileptic drugs such as
lamotrigine used in the treatment of idiophatic
myoclonic seizures and furthermore useful in
females. In fact, it is very well-known in the litera-
ture that lamotrigine is now widely used as a sub-
stitute for sodium valproate in the treatment of
young female patients who either had sodium
valproate side effects (e.g. ovarii polycystic) or
did not tolerate the drug.11 To date, there are no
reports of endocrinological problems or menstrual
issues with LEV.12 Thus, our results further confirm
that LEV could be tried as the first drug in young
female epileptic patients specially for JME.
Overall, our results confirm that LEV as de novo
(monotherapy) and add-on therapy at doses
between 2000 and 3000 mg/day effectively reduces
myoclonic seizure frequency in patients with idio-
pathic generalised epilepsy.
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